Market research
ZEAL Zealand Pharma A/S ADR
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 814M
- P/E ratio
- Not available
- Analyst target
- 240.78
- Dividend yield
- 0.0%
- Beta
- 1.34
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US98920Y3045
- Market cap
- 814M
- P/E ratio
- Not available
- Analyst target
- 240.78
- Dividend yield
- 0.0%
- Beta
- 1.34
About
About Zealand Pharma A/S ADR
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ZEAL discussion.
5 years, 4 months ago
Zealand Pharma A/S is currently in a long term downtrend where the price is trading 9.0% below its 200 day moving average.
From a valuation standpoint, the stock is 98.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 21.8.
Zealand Pharma A/S's total revenue rose by 451.3% to $63M since the same quarter in the previous year.
Its net income has dropped by 96.5% to $-381M since the same quarter in the previous year.
Finally, its free cash flow fell by 58.9% to $-282M since the same quarter in the previous year.
Based on the above factors, Zealand Pharma A/S gets an overall score of 2/5.